TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32986466

Group type: EXPERIMENTAL
Intervention: Early functional mobilization (EFM) group; immediate postoperative weightbearing and ankle motion.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group; immobilization in a below‐knee plaster cast for 2 weeks.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Early functional mobilization (EFM) group; tendon elongation at 2 weeks: 1.88 cm (mean side‐to‐side difference).
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group; tendon elongation at 2 weeks: 0.71 cm (mean side‐to‐side difference).
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Early functional mobilization (EFM) group; mean Achilles tendon elongation at 1 year: 1.73 (1.07) cm.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group; mean Achilles tendon elongation at 1 year: 1.67 (0.92) cm.
Number of subjects: 86
Study: 36071456

Group type: EXPERIMENTAL
Intervention: Micro-learning intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (traditional learning)
Number of subjects: 46
Study: 33618669

Group type: EXPERIMENTAL
Intervention: Progressive high-intensity 3-month targeted kyphosis exercise and posture training intervention
Number of subjects: 101
Study: 32467502

Group type: COMPARATOR
Intervention: NOACs (dabigatran, rivaroxaban, apixaban)
Number of subjects: 13698

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 13698

Group type: COMPARATOR
Intervention: NOACs vs Warfarin
Number of subjects: 13698

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 13698
Study: 35947391

Group type: EXPERIMENTAL
Intervention: Prior diagnosis in a higher diagnostic class
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Prior diagnosis in a lower diagnostic class
Number of subjects: 149

Group type: COMPARATOR
Intervention: No prior diagnostic information (control)
Number of subjects: 149
Study: 32918827

Group type: EXPERIMENTAL
Intervention: Schisto and Ladders version 2 game
Number of subjects: 275

Group type: COMPARATOR
Intervention: Snakes and Ladders game
Number of subjects: 275
Study: 34942679

Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub followed by povidone-iodine paint (Group B)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Povidone-iodine paint only (Group A)
Number of subjects: 251
Study: 33719027

Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate (FC) 1000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate (FC) 500 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium ferrous citrate (SF) 100 mg/day
Number of subjects: 0
Study: 32539787

Group type: EXPERIMENTAL
Intervention: Group-based worksite intervention utilizing pedometers, group competition, goal setting, and other incentives.
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control group with no intervention applied.
Number of subjects: 398
Study: 35984992

Group type: EXPERIMENTAL
Intervention: Algorithm-based nudges (Conversation Connect) to promote early serious illness conversations (SICs)
Number of subjects: 79
Study: 33711390

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol-based anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane treatment in H9C2 cells
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Up-regulation of THAP11
Number of subjects: 40
Study: 33068140

Group type: EXPERIMENTAL
Intervention: Circulating SHBG concentrations
Number of subjects: 67358
Study: 35320644

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 524

Group type: COMPARATOR
Intervention: Trastuzumab emtansine
Number of subjects: 524
Study: 33810049

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa and Lippia citriodora extract (MetabolAid®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32699327

Group type: EXPERIMENTAL
Intervention: Genetically influenced telomere length (standard deviation increase)
Number of subjects: 173000
Study: 35218727

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Encounter Decision Aid (EDA)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care (for patients)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care (for clinicians)
Number of subjects: 1200
Study: 32071117

Group type: EXPERIMENTAL
Intervention: POWER-remote
Number of subjects: 96

Group type: COMPARATOR
Intervention: self-directed
Number of subjects: 96
Study: 35937673

Group type: EXPERIMENTAL
Intervention: Improved surgical eight-step washing technique
Number of subjects: 800

Group type: COMPARATOR
Intervention: Traditional seven-step washing technique
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 800
Study: 33630435

Group type: EXPERIMENTAL
Intervention: Early surgery (0-30 days after diagnosis)
Number of subjects: 80086

Group type: COMPARATOR
Intervention: Delayed surgery (90-120 days after diagnosis)
Number of subjects: 80086
Study: 35341944

Group type: EXPERIMENTAL
Intervention: Inhalation of Longevity™, a proprietary essential oil blend
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33624184

Group type: EXPERIMENTAL
Intervention: Reldesemtiv 450 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Reldesemtiv 150 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Reldesemtiv (highest peak plasma concentration quartile, Cmax > 3.29 μg/mL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 32304404

Group type: EXPERIMENTAL
Intervention: Tactics to Optimize the Potential
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control
Number of subjects: 128
Study: 33920894

Group type: EXPERIMENTAL
Intervention: Intensified MI-counseling by occupational health physician and health coach (4 telephone counseling sessions)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual hypertension counseling
Number of subjects: 34
Study: 32535124

Group type: EXPERIMENTAL
Intervention: Acute decline in estimated glomerular filtration rate (eGFR)
Number of subjects: 3715

Group type: COMPARATOR
Intervention: Evidence of decongestion (declines in BNP, NT-proBNP, or weight; increases in hematocrit, albumin, or total protein)
Number of subjects: 3715
Study: 35724774

Group type: EXPERIMENTAL
Intervention: 30 mg avasopasem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 90 mg avasopasem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avasopasem (both dosages)
Number of subjects: 0
Study: 33716121

Group type: EXPERIMENTAL
Intervention: Amniotic suspension allograft (ASA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 200
Study: 35021936

Group type: EXPERIMENTAL
Intervention: Condensed version of distributed practice
Number of subjects: 44

Group type: COMPARATOR
Intervention: Extended version of distributed practice
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 34399062

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 440

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 440
Study: 32170634

Group type: EXPERIMENTAL
Intervention: Docetaxel + Cyclophosphamide (TC) for 6 cycles (TC6)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Fluorouracil + Epirubicin + Cyclophosphamide followed by Docetaxel (FEC-TC)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Docetaxel followed by Fluorouracil + Epirubicin + Cyclophosphamide (TC-FEC)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 195
Study: 36415191

Group type: EXPERIMENTAL
Intervention: Serum NETs and sVCAM-1 levels on the 1st day after surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Serum NETs and sVCAM-1 levels on the 3rd day after surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Age, body mass index, knee flexion position, serum NETs and sVCAM-1 levels at 1 and 3 days after operation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Correlation between serum NETs and sVCAM-1 levels at 1 and 3 days after operation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Serum NETs and sVCAM-1 levels at 1 day after operation
Number of subjects: 90
Study: 33245589

Group type: COMPARATOR
Intervention: High-frequency telephone continuing care (10 contacts)
Number of subjects: 240

Group type: COMPARATOR
Intervention: High-frequency text message continuing care (10 contacts)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Low-frequency telephone continuing care (3 contacts)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Low-frequency text message continuing care (3 contacts)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Control group (1 contact)
Number of subjects: 240
Study: 36283851

Group type: EXPERIMENTAL
Intervention: Gastrostomy button securement device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tic-tac-toe dressing
Number of subjects: 0
Study: 34089409

Group type: EXPERIMENTAL
Intervention: Collaborative Care
Number of subjects: 98

Group type: COMPARATOR
Intervention: Enhanced Care
Number of subjects: 98
Study: 32514007

Group type: EXPERIMENTAL
Intervention: Illustrated Consult
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard Consult
Number of subjects: 82
Study: 35323633

Group type: EXPERIMENTAL
Intervention: Traditional Resistance Exercise (TRE)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-Intensity Resistance Exercise with Blood Flow Restriction (LIRE-BFR)
Number of subjects: 17
Study: 32129851

Group type: EXPERIMENTAL
Intervention: Experimental intervention improving access to rapid diagnostic testing (RDT) through community health workers (CHWs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experience and knowledge about RDT and experience with CHWs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted use of ACTs and taking the correct dose, in addition to experience with RDT
Number of subjects: 0
Study: 33574146

Group type: EXPERIMENTAL
Intervention: Neonates with hypothermia
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Number of subjects: 1330

Group type: COMPARATOR
Intervention: Hypothermic neonates
Number of subjects: 1330
Study: 33234634

Group type: EXPERIMENTAL
Intervention: GR1501 (IL-17A targeted monoclonal antibody)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 36215959

Group type: EXPERIMENTAL
Intervention: Trauma Informed Hatha Yoga + Dialectical Behavior Therapy for Substance Use Disorders (DBT‐S)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy for Substance Use Disorders (DBT‐S)
Number of subjects: 39
Study: 34740845

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: McGRATH MAC laryngoscope
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: C‐MAC laryngoscope
Number of subjects: 120
Study: 36174143

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 47

Group type: COMPARATOR
Intervention: Moderate nicotine content (MNC) cigarettes
Number of subjects: 47
Study: 32415555

Group type: EXPERIMENTAL
Intervention: CB 2nd
Number of subjects: 116

Group type: COMPARATOR
Intervention: PVAC Gold
Number of subjects: 116
Study: 32709643

Group type: EXPERIMENTAL
Intervention: Prehospital continuous positive airway pressure (CPAP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 77
Study: 35045226

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA‐1273 booster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNT162b2 booster
Number of subjects: 0

Group type: COMPARATOR
Intervention: No booster
Number of subjects: 0
Study: 34625057

Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 32762109

Group type: EXPERIMENTAL
Intervention: Automated brachial-ankle PWV (baPWV) using Microlife WatchBP Office Vascular
Number of subjects: 97

Group type: COMPARATOR
Intervention: Reference carotid-femoral PWV (cfPWV) using Complior device
Number of subjects: 97

Group type: COMPARATOR
Intervention: Comparison of baPWV and cfPWV
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Correlation with age
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Correlation with systolic blood pressure
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Correlation with carotid intima-media thickness
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Correlation with carotid distensibility coefficient
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Agreement in identifying subjects at top quartile
Number of subjects: 97

Group type: COMPARATOR
Intervention: Areas under the receiver operating characteristic curves for carotid plaques
Number of subjects: 97
Study: 36228662

Group type: EXPERIMENTAL
Intervention: Tailored intersectoral discharge program (TIDP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual rehabilitative care
Number of subjects: 110
Study: 34251106

Group type: EXPERIMENTAL
Intervention: Two-layer posterior reconstruction of the vesicourethral anastomosis (VUA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard technique of the vesicourethral anastomosis (VUA)
Number of subjects: 67
Study: 33512795

Group type: EXPERIMENTAL
Intervention: DCL-101 (3L in cohort 1; 4L in cohort 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 4L PEG-ELS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DCL-101 and 4L PEG-ELS
Number of subjects: 45
Study: 36414367

Group type: EXPERIMENTAL
Intervention: Position change and back massage (PCBM)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Early ambulation (EA)
Number of subjects: 185
Study: 35013615

Group type: EXPERIMENTAL
Intervention: Atezolizumab with enzalutamide
Number of subjects: 759
Study: 33482741

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) with intervention, using an instant report to guide physician's choice of intervention.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard practice without GA intervention.
Number of subjects: 1000
Study: 616852759

Group type: EXPERIMENTAL
Intervention: High-frequency fulguration combined with 5% imiquimod cream
Number of subjects: 112

Group type: COMPARATOR
Intervention: High-frequency fulguration combined with intramuscular injection of Bacillus Calmette-Guerin polysaccharide nucleic acid
Number of subjects: 112
Study: 35771569

Group type: EXPERIMENTAL
Intervention: BG00011 56 mg once-weekly subcutaneous
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BG00011
Number of subjects: 106
Study: 34584280

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 70
Study: 33576291

Group type: EXPERIMENTAL
Intervention: myPlan app
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual web‐based safety planning resources
Number of subjects: 346
Study: 33515990

Group type: EXPERIMENTAL
Intervention: 18F (18.8% fat, 47.6% lactose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 22F (22.3% fat, 42.8% lactose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 26F (26.0% fat, 38.6% lactose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30F (30.1% fat, 33.8% lactose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glucose Tolerance Test (GTT) for 18F
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Glucose Tolerance Test (GTT) for 22F
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Glucose Tolerance Test (GTT) for 26F
Number of subjects: 40
Study: 32179138

Group type: EXPERIMENTAL
Intervention: Camino Verde intervention using community health workers (brigadistas) for dengue prevention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Camino Verde intervention
Number of subjects: 150
Study: 34236302

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch (Laboratorios Gebro Pharma, SA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Versatis 5% lidocaine patch (Grünenthal)
Number of subjects: 5
Study: 34614432

Group type: EXPERIMENTAL
Intervention: Liver resection (LR)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control group (type IV PVTT)
Number of subjects: 627
Study: 33461319

Group type: EXPERIMENTAL
Intervention: Bacterial suspension of P. extremorientalis strain ZJH1 (10 μL of 10^8 CFU/ml) inoculated into healthy P. ternata plants.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sterile water (control) inoculated into healthy P. ternata plants.
Number of subjects: 20
Study: 34820710

Group type: EXPERIMENTAL
Intervention: Intervention telephone health coaching calls
Number of subjects: 14
Study: 34659105

Group type: EXPERIMENTAL
Intervention: Hair cortisol concentration measured at baseline and after 12 months
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Hair cortisol concentration measured at 12 months
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Initial 12‐month increase in log hair cortisol concentration
Number of subjects: 786
Study: 32522790

Group type: EXPERIMENTAL
Intervention: Screening interval of 2 years for type 1 DM
Number of subjects: 25745

Group type: EXPERIMENTAL
Intervention: Screening interval of 3 years for type 2 DM
Number of subjects: 25745

Group type: EXPERIMENTAL
Intervention: Screening interval of 4 years for low-risk patients with type 2 DM
Number of subjects: 25745

Group type: EXPERIMENTAL
Intervention: 10-year cumulative incidence of referable DR for type 1 DM
Number of subjects: 25745

Group type: EXPERIMENTAL
Intervention: 10-year cumulative incidence of referable DR for type 2 DM
Number of subjects: 25745
Study: 33080991

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (laparoscopic cholecystectomy without conversion)
Number of subjects: 263
Study: 34936531

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) for 6 months
Number of subjects: 194

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 6 months
Number of subjects: 194
Study: 32892756

Group type: EXPERIMENTAL
Intervention: Standardised lunch providing 1.5 g/kg body mass of carbohydrate
Number of subjects: 108
Study: 32383574

Group type: EXPERIMENTAL
Intervention: Functional electric stimulation in posturally corrected position (Group 1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Motor program activating therapy (Group 2)
Number of subjects: 44
Study: 35388922

Group type: EXPERIMENTAL
Intervention: 3D-printed models of craniosynostosis
Number of subjects: 85

Group type: COMPARATOR
Intervention: 2D reconstructions of craniosynostosis
Number of subjects: 85
Study: 33616765

Group type: COMPARATOR
Intervention: Control group (G1) received only conventional therapy with occlusal splint (OS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Placebo group (G2) received treatment with OS and LED therapy (device turned off)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: LED therapy (G3) once a week
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: LED therapy (G4) twice a week
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: OS associated with LED therapy (G5) once a week
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: OS therapy plus infrared LED (G6) two sessions per week
Number of subjects: 70
Study: 32761980

Group type: COMPARATOR
Intervention: Zembrin® (25 mg)
Number of subjects: 20
Study: 33544195

Group type: EXPERIMENTAL
Intervention: Combined alcohol (target BrAC 0.08%) and cannabis (12.5% THC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol (target BrAC 0.08%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo alcohol and active cannabis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo alcohol and placebo cannabis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active cannabis (12.5% THC)
Number of subjects: 0
Study: 33166627

Group type: EXPERIMENTAL
Intervention: Phytoconstituents (specifically cannabidiol and tetrahydrocannabinol)
Number of subjects: 50000000

Group type: EXPERIMENTAL
Intervention: Phytoconstituents (cannabidiol and tetrahydrocannabinol)
Number of subjects: 50000000
Study: 36361052

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 90 min once a week for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (non-CBT-I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 60
Study: 35927776

Group type: EXPERIMENTAL
Intervention: Biliary stenting combined with iodine‐125 seed strand implantation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Biliary stent implantation alone (Control group)
Number of subjects: 60
Study: 33421203

Group type: EXPERIMENTAL
Intervention: 100Asp
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 125Asp
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 125Reg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100:25Asp
Number of subjects: 24
Study: 32844517

Group type: EXPERIMENTAL
Intervention: ASD group without language disorder
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (typically developing)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: DLD group
Number of subjects: 3
Study: 35912159

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided sciatic nerve block anesthesia (UG-SNBA) under 3D reconstruction algorithm
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sciatic nerve block anesthesia (SNBA)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided sciatic nerve block anesthesia (UG-SNBA)
Number of subjects: 68
Study: 33515092

Group type: EXPERIMENTAL
Intervention: 50 g glucose with 25 g pea protein (Test 1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 50 g glucose with 50 g pea protein (Test 2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 50 g glucose (Control)
Number of subjects: 31